Literature DB >> 27427922

Comparable outcomes following two or three cycles of high-dose chemotherapy and autologous stem cell transplantation for patients with relapsed/refractory germ cell tumors.

Z DeFilipp1, C B Rosand1, D A Goldstein1, V A Master2, B C Carthon1, W B Harris1, O Kucuk1, Z Al-Kadhimi1, J B Cohen1, C R Flowers1, M J Lechowicz1, A K Nooka1, J L Kaufman1, A A Langston1, Z Chen3, J Arora3, E K Waller1.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 27427922     DOI： 10.1038/bmt.2016.189

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  15 in total

Review 1.  High-dose chemotherapy and stem cell transplantation for advanced testicular cancer.

Authors:  Martin H Voss; Darren R Feldman; Robert J Motzer
Journal:  Expert Rev Anticancer Ther       Date:  2011-07       Impact factor: 4.512

2.  Extragonadal germ cell tumors of the mediastinum and retroperitoneum: results from an international analysis.

Authors:  Carsten Bokemeyer; Craig R Nichols; Jean-P Droz; Hans-J Schmoll; Alan Horwich; Arthur Gerl; Sophie D Fossa; Jörg Beyer; Jörg Pont; Lothar Kanz; Lawrence Einhorn; Jörg T Hartmann
Journal:  J Clin Oncol       Date:  2002-04-01       Impact factor: 44.544

3.  A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours.

Authors:  J-L Pico; G Rosti; A Kramar; H Wandt; V Koza; R Salvioni; C Theodore; G Lelli; W Siegert; A Horwich; M Marangolo; W Linkesch; G Pizzocaro; H-J Schmoll; J Bouzy; J-P Droz; P Biron
Journal:  Ann Oncol       Date:  2005-05-31       Impact factor: 32.976

4.  International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group.

Authors: 
Journal:  J Clin Oncol       Date:  1997-02       Impact factor: 44.544

5.  TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: results and prognostic factor analysis.

Authors:  Darren R Feldman; Joel Sheinfeld; Dean F Bajorin; Patricia Fischer; Stefan Turkula; Nicole Ishill; Sujata Patil; Manjit Bains; Lilian M Reich; George J Bosl; Robert J Motzer
Journal:  J Clin Oncol       Date:  2010-03-01       Impact factor: 44.544

6.  Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy.

Authors:  Anja Lorch; Jörg Beyer; Caroline Bascoul-Mollevi; Andrew Kramar; Lawrence H Einhorn; Andrea Necchi; Christophe Massard; Ugo De Giorgi; Aude Fléchon; Kim A Margolin; Jean-Pierre Lotz; Jose Ramon Germa Lluch; Thomas Powles; Christian K Kollmannsberger
Journal:  J Clin Oncol       Date:  2010-10-18       Impact factor: 44.544

7.  Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors.

Authors:  Robert J Motzer; Craig J Nichols; Kim A Margolin; Jennifer Bacik; Paul G Richardson; Nicholas J Vogelzang; Dean F Bajorin; Primo N Lara; Lawrence Einhorn; Madhu Mazumdar; George J Bosl
Journal:  J Clin Oncol       Date:  2007-01-20       Impact factor: 44.544

Review 8.  Medical treatment of advanced testicular cancer.

Authors:  Darren R Feldman; George J Bosl; Joel Sheinfeld; Robert J Motzer
Journal:  JAMA       Date:  2008-02-13       Impact factor: 56.272

Review 9.  High-dose chemotherapy for germ cell tumors: do we have a model?

Authors:  Andrea Necchi; Francesco Lanza; Giovanni Rosti; Massimo Martino; Elena Farè; Paolo Pedrazzoli
Journal:  Expert Opin Biol Ther       Date:  2014-09-22       Impact factor: 4.388

10.  Single versus sequential high-dose chemotherapy in patients with relapsed or refractory germ cell tumors: a prospective randomized multicenter trial of the German Testicular Cancer Study Group.

Authors:  Anja Lorch; Christian Kollmannsberger; Joerg Thomas Hartmann; Bernd Metzner; Ingo G H Schmidt-Wolf; Wolfgang E Berdel; Florian Weissinger; Jan Schleicher; Gerlinde Egerer; Antje Haas; Rebekka Schirren; Jörg Beyer; Carsten Bokemeyer; Oliver Rick
Journal:  J Clin Oncol       Date:  2007-07-01       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.